Betaglycan Gene (TGFBR3) Polymorphism Is Associated with Increased Risk of Endometrial Cancer
We investigated single nucleotide polymorphism (SNP) of the betaglycan gene (TGFBR3) encoding the TGFβ co-receptor in endometrial cancer (EC) and its association with betaglycan expression. The study group included 153 women diagnosed with EC and 248 cancer-free controls. SNP genotyping and gene exp...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical medicine 2020-09, Vol.9 (10), p.3082 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 10 |
| container_start_page | 3082 |
| container_title | Journal of clinical medicine |
| container_volume | 9 |
| creator | Zakrzewski, Piotr K. Forma, Ewa Cygankiewicz, Adam I. Bryś, Magdalena Wójcik-Krowiranda, Katarzyna Bieńkiewicz, Andrzej Semczuk, Andrzej Krajewska, Wanda M. |
| description | We investigated single nucleotide polymorphism (SNP) of the betaglycan gene (TGFBR3) encoding the TGFβ co-receptor in endometrial cancer (EC) and its association with betaglycan expression. The study group included 153 women diagnosed with EC and 248 cancer-free controls. SNP genotyping and gene expression were analyzed using TaqMan probes. Three out of the eight SNPs tested, i.e., rs12566180 (CT; OR = 2.22; 95% CI = 1.15–4.30; p = 0.0177), rs6680463 (GC; OR = 2.34; 95% CI = 1.20–4.53; p = 0.0120) and rs2296621 (TT; OR = 6.40; 95% CI = 1.18–34.84; p = 0.0317) were found to be significantly associated with increased risk of EC (adjusted to age, body mass index, menarche and parity). Among the analyzed SNPs, only rs2296621 demonstrated the impact on the increased cancer aggressiveness evaluated by the WHO grading system (G3 vs. G1/2, GT—OR = 4.04; 95% CI = 1.56–10.51; p = 0.0026; T—OR = 2.38; 95% CI = 1.16–4.85; p = 0.0151). Linkage disequilibrium (LD) analysis revealed high LD (r2 ≥ 0.8) in two haploblocks, constructed by rs2770186/rs12141128 and rs12566180/rs6680463, respectively. In the case of C/C haplotype (OR = 4.82; 95% CI = 1.54–15.07; p = 0.0116—Bonferroni corrected) and T/G haplotype (OR = 3.25; 95% CI = 1.29–8.15; p = 0.0328—Bonferroni corrected) in haploblock rs12566180/rs6680463, significantly higher frequency was observed in patients with EC as compared to the control group. The genotype-phenotype studies showed that SNPs of the TGFBR3 gene associated with an increased risk of EC, i.e., rs12566180 and rs2296621 may affect betaglycan expression at the transcriptomic level (rs12566180—CC vs. TT, p < 0.01; rs2296621—GG vs. TT, p < 0.001, GT vs. TT, p < 0.05). Functional consequences of evaluated TGFBR3 gene SNPs were supported by RegulomeDB search. In conclusion, polymorphism of the TGFBR3 gene may be associated with an increased EC occurrence, as well as may be the molecular mechanism responsible for observed betaglycan down-regulation in EC patients. |
| doi_str_mv | 10.3390/jcm9103082 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7650668</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2447310657</sourcerecordid><originalsourceid>FETCH-LOGICAL-c383t-2674325c1f3366d26c4d30fc01a2b9d41472c0943f72a05a6ff60797d4304f103</originalsourceid><addsrcrecordid>eNpdkVtLAzEQhYMottS--AsCvlRhNbcmuy9CW7QWBEX0UULMJm3qblKTXaX_3hXF27zMDPNxOIcB4BCjU0oLdLbWdYERRTnZAX2ChMgQzenur7kHhimtUVd5zggW-6BHSZGLnPA-eJyaRi2rrVYezo03cHQ_v5ze0WN4G6ptHeJm5VINFwlOUgraqcaU8M01K7jwOhqVuvXOpWcYLLzwZahNE52q4Ex5beIB2LOqSmb41Qfg4fLifnaVXd_MF7PJdaY7f01GuGCUjDW2lHJeEq5ZSZHVCCvyVJQMM0E0Khi1gig0VtxajkQhSkYRs136ATj_1N20T7UptfFNVJXcRFeruJVBOfn34t1KLsOrFHyMOM87gdGXQAwvrUmNrF3SpqqUN6FNkjAmKEZ8LDr06B-6Dm30XTxJOMOdV04-qJNPSseQUjT22wxG8uNx8udx9B0ExYd_</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2641147627</pqid></control><display><type>article</type><title>Betaglycan Gene (TGFBR3) Polymorphism Is Associated with Increased Risk of Endometrial Cancer</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Zakrzewski, Piotr K. ; Forma, Ewa ; Cygankiewicz, Adam I. ; Bryś, Magdalena ; Wójcik-Krowiranda, Katarzyna ; Bieńkiewicz, Andrzej ; Semczuk, Andrzej ; Krajewska, Wanda M.</creator><creatorcontrib>Zakrzewski, Piotr K. ; Forma, Ewa ; Cygankiewicz, Adam I. ; Bryś, Magdalena ; Wójcik-Krowiranda, Katarzyna ; Bieńkiewicz, Andrzej ; Semczuk, Andrzej ; Krajewska, Wanda M.</creatorcontrib><description>We investigated single nucleotide polymorphism (SNP) of the betaglycan gene (TGFBR3) encoding the TGFβ co-receptor in endometrial cancer (EC) and its association with betaglycan expression. The study group included 153 women diagnosed with EC and 248 cancer-free controls. SNP genotyping and gene expression were analyzed using TaqMan probes. Three out of the eight SNPs tested, i.e., rs12566180 (CT; OR = 2.22; 95% CI = 1.15–4.30; p = 0.0177), rs6680463 (GC; OR = 2.34; 95% CI = 1.20–4.53; p = 0.0120) and rs2296621 (TT; OR = 6.40; 95% CI = 1.18–34.84; p = 0.0317) were found to be significantly associated with increased risk of EC (adjusted to age, body mass index, menarche and parity). Among the analyzed SNPs, only rs2296621 demonstrated the impact on the increased cancer aggressiveness evaluated by the WHO grading system (G3 vs. G1/2, GT—OR = 4.04; 95% CI = 1.56–10.51; p = 0.0026; T—OR = 2.38; 95% CI = 1.16–4.85; p = 0.0151). Linkage disequilibrium (LD) analysis revealed high LD (r2 ≥ 0.8) in two haploblocks, constructed by rs2770186/rs12141128 and rs12566180/rs6680463, respectively. In the case of C/C haplotype (OR = 4.82; 95% CI = 1.54–15.07; p = 0.0116—Bonferroni corrected) and T/G haplotype (OR = 3.25; 95% CI = 1.29–8.15; p = 0.0328—Bonferroni corrected) in haploblock rs12566180/rs6680463, significantly higher frequency was observed in patients with EC as compared to the control group. The genotype-phenotype studies showed that SNPs of the TGFBR3 gene associated with an increased risk of EC, i.e., rs12566180 and rs2296621 may affect betaglycan expression at the transcriptomic level (rs12566180—CC vs. TT, p < 0.01; rs2296621—GG vs. TT, p < 0.001, GT vs. TT, p < 0.05). Functional consequences of evaluated TGFBR3 gene SNPs were supported by RegulomeDB search. In conclusion, polymorphism of the TGFBR3 gene may be associated with an increased EC occurrence, as well as may be the molecular mechanism responsible for observed betaglycan down-regulation in EC patients.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm9103082</identifier><identifier>PMID: 32987826</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Bioethics ; Cancer therapies ; Clinical medicine ; Endometrial cancer ; Endometrium ; Gene expression ; Genetic testing ; Kinases ; Medical prognosis ; Menarche ; Mutation ; Polymorphism ; Population ; Sociodemographics ; Surgery ; Tumors</subject><ispartof>Journal of clinical medicine, 2020-09, Vol.9 (10), p.3082</ispartof><rights>2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c383t-2674325c1f3366d26c4d30fc01a2b9d41472c0943f72a05a6ff60797d4304f103</citedby><cites>FETCH-LOGICAL-c383t-2674325c1f3366d26c4d30fc01a2b9d41472c0943f72a05a6ff60797d4304f103</cites><orcidid>0000-0002-7205-8901 ; 0000-0001-5807-2654 ; 0000-0002-1450-3712 ; 0000-0003-0230-6831 ; 0000-0002-7725-5429</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650668/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650668/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Zakrzewski, Piotr K.</creatorcontrib><creatorcontrib>Forma, Ewa</creatorcontrib><creatorcontrib>Cygankiewicz, Adam I.</creatorcontrib><creatorcontrib>Bryś, Magdalena</creatorcontrib><creatorcontrib>Wójcik-Krowiranda, Katarzyna</creatorcontrib><creatorcontrib>Bieńkiewicz, Andrzej</creatorcontrib><creatorcontrib>Semczuk, Andrzej</creatorcontrib><creatorcontrib>Krajewska, Wanda M.</creatorcontrib><title>Betaglycan Gene (TGFBR3) Polymorphism Is Associated with Increased Risk of Endometrial Cancer</title><title>Journal of clinical medicine</title><description>We investigated single nucleotide polymorphism (SNP) of the betaglycan gene (TGFBR3) encoding the TGFβ co-receptor in endometrial cancer (EC) and its association with betaglycan expression. The study group included 153 women diagnosed with EC and 248 cancer-free controls. SNP genotyping and gene expression were analyzed using TaqMan probes. Three out of the eight SNPs tested, i.e., rs12566180 (CT; OR = 2.22; 95% CI = 1.15–4.30; p = 0.0177), rs6680463 (GC; OR = 2.34; 95% CI = 1.20–4.53; p = 0.0120) and rs2296621 (TT; OR = 6.40; 95% CI = 1.18–34.84; p = 0.0317) were found to be significantly associated with increased risk of EC (adjusted to age, body mass index, menarche and parity). Among the analyzed SNPs, only rs2296621 demonstrated the impact on the increased cancer aggressiveness evaluated by the WHO grading system (G3 vs. G1/2, GT—OR = 4.04; 95% CI = 1.56–10.51; p = 0.0026; T—OR = 2.38; 95% CI = 1.16–4.85; p = 0.0151). Linkage disequilibrium (LD) analysis revealed high LD (r2 ≥ 0.8) in two haploblocks, constructed by rs2770186/rs12141128 and rs12566180/rs6680463, respectively. In the case of C/C haplotype (OR = 4.82; 95% CI = 1.54–15.07; p = 0.0116—Bonferroni corrected) and T/G haplotype (OR = 3.25; 95% CI = 1.29–8.15; p = 0.0328—Bonferroni corrected) in haploblock rs12566180/rs6680463, significantly higher frequency was observed in patients with EC as compared to the control group. The genotype-phenotype studies showed that SNPs of the TGFBR3 gene associated with an increased risk of EC, i.e., rs12566180 and rs2296621 may affect betaglycan expression at the transcriptomic level (rs12566180—CC vs. TT, p < 0.01; rs2296621—GG vs. TT, p < 0.001, GT vs. TT, p < 0.05). Functional consequences of evaluated TGFBR3 gene SNPs were supported by RegulomeDB search. In conclusion, polymorphism of the TGFBR3 gene may be associated with an increased EC occurrence, as well as may be the molecular mechanism responsible for observed betaglycan down-regulation in EC patients.</description><subject>Bioethics</subject><subject>Cancer therapies</subject><subject>Clinical medicine</subject><subject>Endometrial cancer</subject><subject>Endometrium</subject><subject>Gene expression</subject><subject>Genetic testing</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>Menarche</subject><subject>Mutation</subject><subject>Polymorphism</subject><subject>Population</subject><subject>Sociodemographics</subject><subject>Surgery</subject><subject>Tumors</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkVtLAzEQhYMottS--AsCvlRhNbcmuy9CW7QWBEX0UULMJm3qblKTXaX_3hXF27zMDPNxOIcB4BCjU0oLdLbWdYERRTnZAX2ChMgQzenur7kHhimtUVd5zggW-6BHSZGLnPA-eJyaRi2rrVYezo03cHQ_v5ze0WN4G6ptHeJm5VINFwlOUgraqcaU8M01K7jwOhqVuvXOpWcYLLzwZahNE52q4Ex5beIB2LOqSmb41Qfg4fLifnaVXd_MF7PJdaY7f01GuGCUjDW2lHJeEq5ZSZHVCCvyVJQMM0E0Khi1gig0VtxajkQhSkYRs136ATj_1N20T7UptfFNVJXcRFeruJVBOfn34t1KLsOrFHyMOM87gdGXQAwvrUmNrF3SpqqUN6FNkjAmKEZ8LDr06B-6Dm30XTxJOMOdV04-qJNPSseQUjT22wxG8uNx8udx9B0ExYd_</recordid><startdate>20200924</startdate><enddate>20200924</enddate><creator>Zakrzewski, Piotr K.</creator><creator>Forma, Ewa</creator><creator>Cygankiewicz, Adam I.</creator><creator>Bryś, Magdalena</creator><creator>Wójcik-Krowiranda, Katarzyna</creator><creator>Bieńkiewicz, Andrzej</creator><creator>Semczuk, Andrzej</creator><creator>Krajewska, Wanda M.</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7205-8901</orcidid><orcidid>https://orcid.org/0000-0001-5807-2654</orcidid><orcidid>https://orcid.org/0000-0002-1450-3712</orcidid><orcidid>https://orcid.org/0000-0003-0230-6831</orcidid><orcidid>https://orcid.org/0000-0002-7725-5429</orcidid></search><sort><creationdate>20200924</creationdate><title>Betaglycan Gene (TGFBR3) Polymorphism Is Associated with Increased Risk of Endometrial Cancer</title><author>Zakrzewski, Piotr K. ; Forma, Ewa ; Cygankiewicz, Adam I. ; Bryś, Magdalena ; Wójcik-Krowiranda, Katarzyna ; Bieńkiewicz, Andrzej ; Semczuk, Andrzej ; Krajewska, Wanda M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c383t-2674325c1f3366d26c4d30fc01a2b9d41472c0943f72a05a6ff60797d4304f103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Bioethics</topic><topic>Cancer therapies</topic><topic>Clinical medicine</topic><topic>Endometrial cancer</topic><topic>Endometrium</topic><topic>Gene expression</topic><topic>Genetic testing</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>Menarche</topic><topic>Mutation</topic><topic>Polymorphism</topic><topic>Population</topic><topic>Sociodemographics</topic><topic>Surgery</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zakrzewski, Piotr K.</creatorcontrib><creatorcontrib>Forma, Ewa</creatorcontrib><creatorcontrib>Cygankiewicz, Adam I.</creatorcontrib><creatorcontrib>Bryś, Magdalena</creatorcontrib><creatorcontrib>Wójcik-Krowiranda, Katarzyna</creatorcontrib><creatorcontrib>Bieńkiewicz, Andrzej</creatorcontrib><creatorcontrib>Semczuk, Andrzej</creatorcontrib><creatorcontrib>Krajewska, Wanda M.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zakrzewski, Piotr K.</au><au>Forma, Ewa</au><au>Cygankiewicz, Adam I.</au><au>Bryś, Magdalena</au><au>Wójcik-Krowiranda, Katarzyna</au><au>Bieńkiewicz, Andrzej</au><au>Semczuk, Andrzej</au><au>Krajewska, Wanda M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Betaglycan Gene (TGFBR3) Polymorphism Is Associated with Increased Risk of Endometrial Cancer</atitle><jtitle>Journal of clinical medicine</jtitle><date>2020-09-24</date><risdate>2020</risdate><volume>9</volume><issue>10</issue><spage>3082</spage><pages>3082-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>We investigated single nucleotide polymorphism (SNP) of the betaglycan gene (TGFBR3) encoding the TGFβ co-receptor in endometrial cancer (EC) and its association with betaglycan expression. The study group included 153 women diagnosed with EC and 248 cancer-free controls. SNP genotyping and gene expression were analyzed using TaqMan probes. Three out of the eight SNPs tested, i.e., rs12566180 (CT; OR = 2.22; 95% CI = 1.15–4.30; p = 0.0177), rs6680463 (GC; OR = 2.34; 95% CI = 1.20–4.53; p = 0.0120) and rs2296621 (TT; OR = 6.40; 95% CI = 1.18–34.84; p = 0.0317) were found to be significantly associated with increased risk of EC (adjusted to age, body mass index, menarche and parity). Among the analyzed SNPs, only rs2296621 demonstrated the impact on the increased cancer aggressiveness evaluated by the WHO grading system (G3 vs. G1/2, GT—OR = 4.04; 95% CI = 1.56–10.51; p = 0.0026; T—OR = 2.38; 95% CI = 1.16–4.85; p = 0.0151). Linkage disequilibrium (LD) analysis revealed high LD (r2 ≥ 0.8) in two haploblocks, constructed by rs2770186/rs12141128 and rs12566180/rs6680463, respectively. In the case of C/C haplotype (OR = 4.82; 95% CI = 1.54–15.07; p = 0.0116—Bonferroni corrected) and T/G haplotype (OR = 3.25; 95% CI = 1.29–8.15; p = 0.0328—Bonferroni corrected) in haploblock rs12566180/rs6680463, significantly higher frequency was observed in patients with EC as compared to the control group. The genotype-phenotype studies showed that SNPs of the TGFBR3 gene associated with an increased risk of EC, i.e., rs12566180 and rs2296621 may affect betaglycan expression at the transcriptomic level (rs12566180—CC vs. TT, p < 0.01; rs2296621—GG vs. TT, p < 0.001, GT vs. TT, p < 0.05). Functional consequences of evaluated TGFBR3 gene SNPs were supported by RegulomeDB search. In conclusion, polymorphism of the TGFBR3 gene may be associated with an increased EC occurrence, as well as may be the molecular mechanism responsible for observed betaglycan down-regulation in EC patients.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>32987826</pmid><doi>10.3390/jcm9103082</doi><orcidid>https://orcid.org/0000-0002-7205-8901</orcidid><orcidid>https://orcid.org/0000-0001-5807-2654</orcidid><orcidid>https://orcid.org/0000-0002-1450-3712</orcidid><orcidid>https://orcid.org/0000-0003-0230-6831</orcidid><orcidid>https://orcid.org/0000-0002-7725-5429</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2077-0383 |
| ispartof | Journal of clinical medicine, 2020-09, Vol.9 (10), p.3082 |
| issn | 2077-0383 2077-0383 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7650668 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Bioethics Cancer therapies Clinical medicine Endometrial cancer Endometrium Gene expression Genetic testing Kinases Medical prognosis Menarche Mutation Polymorphism Population Sociodemographics Surgery Tumors |
| title | Betaglycan Gene (TGFBR3) Polymorphism Is Associated with Increased Risk of Endometrial Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T04%3A22%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Betaglycan%20Gene%20(TGFBR3)%20Polymorphism%20Is%20Associated%20with%20Increased%20Risk%20of%20Endometrial%20Cancer&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Zakrzewski,%20Piotr%20K.&rft.date=2020-09-24&rft.volume=9&rft.issue=10&rft.spage=3082&rft.pages=3082-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm9103082&rft_dat=%3Cproquest_pubme%3E2447310657%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2641147627&rft_id=info:pmid/32987826&rfr_iscdi=true |